FedCircuitBlog

Here is an update on recent activity at the Supreme Court in cases decided by the Federal Circuit.

• Four new waivers of right to respond were filed with the Court.
• The Court denied the petitions for writ of certiorari in three cases.

Here are the details.

• Federal Circuit Statistics – 2020 Edition – Jason Rantanen analyzes the data and trends in the cases heard and decided by the Federal Circuit this year.
• Gilead “Rewriting” History To Save $2.5B IP Win, Justices Told – Idenix Pharmaceuticals implored the Supreme Court to grant certiorari and reinstate the country’s largest patent verdict after the Federal Circuit reversed the lower court’s decision.
• What to Watch in 2021: IP Stakeholders Offer Predictions and Thoughts for the New Year – Several contributors shared their opinions on the state of intellectual property, the Federal Circuit, and the USPTO going forward into the new year.

Here’s the latest.

• Supreme Court Denies Patent Petitions on Arthrex, Eligibility – The U.S. Supreme Court denied petitions for certiorari in two cases coming out of the Federal Circuit: IYM Technologies LLC v. RPX Corporation and Advanced Micro Devices, Inc. and WhitServe LLC v. Donuts Inc.
• Amgen, GSK Urge Justices To Allow Patents On Genus Claims – A trio of amicus briefs filed on Monday urge the Supreme Court to grant Merck’s petition for certiorari and ensure that companies are able to patent genus claims.
• COVID-19 Vaccine Leader Moderna “Not Aware of Any Significant Intellectual Property Impediments” in Development of its Vaccine Despite Mixed Results at PTAB – As global leaders in COVID-19 vaccine development receive promising results from their clinical trials, the focus turns to whether legal intellectual property obstacles may impede vaccine distribution.  

Here’s the latest.

This post summarizes recent activity at the Supreme Court in cases decided by the Federal Circuit.

• The Supreme Court received three new petitions for writ of certiorari in (1) InfoBionic, Inc. v. Cardionet, LLC, (2) Lone Star Silicon Innovations, LLC v. Iancu, and (3) Kinghorn v. United States.
• Two new responses to petitions were filed with the Court, the first by the Alfred E. Mann Foundation in Cochlear Corp. v. Alfred E. Mann Foundation for Scientific Research, and the second by the government in ThermoLife International LLC v. Iancu.
• One new reply to the petition in Rovi Guides, Inc. v. Comcast Cable Communications, LLC was filed with the Court by Rovi.
• Three amicus briefs were filed in Idenix Pharmaceuticals LLC v. Gilead Sciences, Inc., all in support of Idenix.
• Lastly, the Supreme Court denied the petitions for writ of certiorari in three cases: (1) IYM Technologies LLC v. RPX Corp., (2) Duke University v. Biomarin Pharmaceutical Inc., and (3) Whitserve LLC v. Donuts Inc.

Here are the details.

This post summarizes recent activity at the Supreme Court in cases decided by the Federal Circuit.

• The Supreme Court received two new petitions this week in Fredman Bros. Furniture Co. v. Bedgear, LLC and Idenix Pharmaceuticals LLC v. Gilead Sciences, Inc.
• One reply brief was filed with the Court by B.E. Technology in B.E. Technology, L.L.C. v. Facebook, Inc.
• One amicus brief was filed with the Court in Arctic Cat Inc. v. Bombardier Recreational Products Inc. by Lambeth Magnetic Structures.
• Finally, three waivers of right to respond were filed with the Court in (1) Robles v. Wilkie, (2) Golden v. United States, and (3) Medina v. Federal Aviation Administration.

Here are the details.

Here is an update on recent en banc activity at the Federal Circuit in patent cases. Highlights include three new petitions raising questions related to prosecution history estoppel and vitiation and the denial of three petitions raising questions related to the Appointments Clause, definiteness, written description, and enablement. Here are the details.

Here is an update on recent en banc activity at the Federal Circuit in patent cases. Highlights include new petitions filed in four cases raising questions relating to patent eligibility, the Appointments Clause, claim construction, and non-obviousness; one new response to a pending petition raising questions related to enablement, written description, and the 7th Amendment; and the denial of ten petitions raising issues including the Appointments Clause, claim construction, and implied licenses. Here are the details.

Here is an update on recent en banc activity at the Federal Circuit in patent cases. Highlights include four new petitions related to administrative law, enablement, collateral estoppel, and the doctrine of equivalents; two responses to petitions related to patent eligibility and transfer; one new amicus brief in support of a petition concerning non-obviousness; and the denial of three petitions related to non-obviousness, enablement, written description, and statutory experimental use. Here are the details.

Here is an update on recent en banc activity at the Federal Circuit in patent cases. Highlights include one new petition related to obviousness, one response to a petition related to design patents, two requests for responses to petitions related to Arthrex and transfer, two amicus briefs in support of petitions related to the written description and enablement requirements, and the denial of one petition related to Arthrex and obviousness. Here are the details.

Here is an update on recent en banc activity at the Federal Circuit in patent cases. Highlights include four new petitions, responses to petitions in two cases (including three responses in Arthrex, Inc. v. Smith & Nephew, Inc.), and the denial of a petition along with a dissenting opinion in the same case. Here are the details.